[Maintenance therapy for acute myeloid leukemia (including in patients who have undergone transplantation) including off-label use drugs in Japan].
Rinsho Ketsueki
; 62(8): 978-987, 2021.
Article
en Ja
| MEDLINE
| ID: mdl-34497238
ABSTRACT
Recurrence in acute myeloid leukemia (AML) is a major barrier in patients who achieve complete remission after induction of remission and consolidation therapy and desire long-term survival. Allogeneic hematopoietic stem cell transplantation lowers recurrence risk in patients; however, recurrence is common even after transplantation. Many maintenance therapies for AML aim to lower recurrence risk; therefore, research has focused on identifying drugs with a tolerable adverse-effect profile. Thus far, many trials of cytotoxic anticancer drugs used in maintenance therapy have showed no improvement in survival rates. In contrast, recent studies on immunomodulation, epigenetics, molecular-targeted drugs, etc. have demonstrated promising results. Therefore, we plan to review various maintenance therapies, such as immunotherapy, demethylating agents, and targeted therapies (including fms-like tyrosine kinase 3 inhibitors in particular) based on the current evidence. Moreover, we describe a new strategy that incorporates the assessment of measurable minimal residual disease.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Preparaciones Farmacéuticas
/
Leucemia Mieloide Aguda
/
Trasplante de Células Madre Hematopoyéticas
Límite:
Humans
País como asunto:
Asia
Idioma:
Ja
Año:
2021
Tipo del documento:
Article